Clinical Trial · NCT02139371

Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

Overview

The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and less aggressive tumors. This is a first in human study to test the radiotracer in cancer patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging (1,3 and 24 hours post injection).

Phase

Early Phase 1

Contacts

Dorthe Skovgaard, MD, Phd (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02139371

Drug / Compound

AE105

Isotope(s):
Target(s):
  • uPAR
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • clinical diagnosis of cancer of prostate, breast or urinary bladder

Exclusion

  • pregnancy
  • contraindication for the use of intravenous CT contrast-agencies
  • claustrophobia
  • lactation